ACAD (Biotechnology) Stock Valuation & Fair Value Significantly overvalued
ACAD (Biotechnology) trades at a blended P/E of 22.4, about 139% above its historical normal valuation, with a forward growth estimate of 1.1% and a PEG of 19.84. Analysts' one-year estimates have been hit 27% of the time.
Valuation flags
- Overvalued by 139%
- High PEG (19.8x)
- Low growth forecast
Frequently asked questions
Is ACAD overvalued?
At a blended P/E of 22.4 versus its historical normal P/E of 9.4, ACAD trades about 139% above its typical valuation, with a PEG of 19.84 on 1.1% forward growth. tickerseer currently rates it significantly overvalued.
What is ACAD's fair value and PEG?
ACAD trades at a blended P/E of 22.4 against a historical normal P/E of 9.4, a PEG of 19.84, and a forward growth estimate of 1.1%.
Has tickerseer's rating of ACAD changed?
tickerseer's rating has been significantly overvalued since 2026-07-31.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.